State of Phase 3 Clinical Development in Alzheimer's Disease

This report examines the current landscape of Phase 3 clinical development in Alzheimer's disease (AD), highlighting the challenges and failures that characterize this field. It outlines the historical context of AD development, noting that despite increased research efforts, significant breakthroughs have been limited. The analysis tracks 19 active Phase 3 programs involving 16 unique drugs, revealing a concerning trend where many programs target already validated mechanisms or revisit previously explored pathways, indicating a lack of true innovation. The report applies a Probability of Technical and Regulatory Success (PTRS) methodology to assess these programs, finding that even those with above-average scores often depend on prior approvals or novelty without clear mechanisms. Furthermore, the report discusses the broader challenges faced in late-stage development, including slow disease progression, high costs, and the complexities of measuring clinical outcomes. It concludes with insights into decision-making for clinical development teams and portfolio strategists navigating this high-risk environment.